<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514796</url>
  </required_header>
  <id_info>
    <org_study_id>SB5-1003</org_study_id>
    <nct_id>NCT04514796</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Single-blind, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate to compare the pharmacokinetics, safety, tolerability, and&#xD;
      immunogenicity of two formulations of SB5 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Maximum serum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Area under the concentration-time curve from time zero to the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Apparent volume of distribution during the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Apparent total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCextrap</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Percentage of AUCinf due to extrapolation from time of last measurable concentration (Tlast) to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Experience at least 1 TEAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Experience at least 1 SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs)</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Incidence of ADAs to adalimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutralising antibodies (NAbs)</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Incidence of NAbs to adalimumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>40 mg/0.4 mL of SB5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg/mL of SB5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg/0.8 mL of SB5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg/mL of SB5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>SB5 (adalimumab), 40 mg, single-dose</description>
    <arm_group_label>40 mg/0.4 mL of SB5</arm_group_label>
    <arm_group_label>40 mg/0.8 mL of SB5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Healthy male, aged 18-55 years (inclusive).&#xD;
&#xD;
          2. A body weight between 65.0-90.0 kg (inclusive) and a body mass index between 20.0-29.9&#xD;
             kg/m2 (inclusive)&#xD;
&#xD;
          3. 12-lead electrocardiogram results without clinically significant abnormal.&#xD;
&#xD;
          4. Systolic blood pressure ≤ 140 and ≥ 90 mmHg, diastolic blood pressure ≤ 90 and ≥ 50&#xD;
             mmHg and pulse rate ≥ 45 and ≤ 90 beats per minute or assessed as not clinically&#xD;
             significant.&#xD;
&#xD;
          5. Physical examination results without clinically significant abnormal findings.&#xD;
&#xD;
          6. Clinical laboratory results within the normal range or outside the normal range but&#xD;
             assessed as not clinically significant.&#xD;
&#xD;
          7. Male subjects who did not have surgical sterilisation must be willing to abstain from&#xD;
             sexual intercourse or willing to use a condom in addition to having their female&#xD;
             partner use another form of contraception such as an intra-uterine device, oral&#xD;
             contraceptive, injectable progesterone, sub-dermal implant, or a tubal ligation unless&#xD;
             their partners are infertile from the time of the investigational product (IP)&#xD;
             administration until 5 months after the IP administration.&#xD;
&#xD;
          8. Willing and able to comply with study procedures including lifestyle consideration.&#xD;
&#xD;
          9. Able to provide written informed consent prior to any study procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. A history and/or current presence of clinically significant atopic, hypersensitivity&#xD;
             or allergic, also including known or suspected clinically relevant drug&#xD;
             hypersensitivity to adalimumab or to any of the excipients.&#xD;
&#xD;
          2. A history of and/or current clinically significant gastrointestinal, renal, hepatic,&#xD;
             haematological, pulmonary, neurologic, psychiatric, drug or alcohol abuse, or allergic&#xD;
             disease excluding mild asymptotic seasonal allergies.&#xD;
&#xD;
          3. Either active or latent tuberculosis (TB) or a history of TB.&#xD;
&#xD;
          4. A history of invasive systemic fungal infections or other opportunistic infections.&#xD;
&#xD;
          5. A history of any systemic or local infection, a known risk for developing sepsis&#xD;
             and/or known active inflammatory process within 180 days prior to Randomisation.&#xD;
&#xD;
          6. A sign of ongoing or chronic inflammation process defined as high blood concentration&#xD;
             of C reactive protein (&gt; 1.5 times the upper limit of normal).&#xD;
&#xD;
          7. A history of serious infection (associated with hospitalisation and/or which required&#xD;
             intravenous antibiotics) within 180 days prior to Randomisation.&#xD;
&#xD;
          8. Previously been treated with adalimumab.&#xD;
&#xD;
          9. Previously been exposed to a monoclonal antibody or fusion protein (other than&#xD;
             adalimumab) within 180 days prior to Randomisation and/or there is a confirmed&#xD;
             evidence or clinical suspicion of immunogenicity from previous exposure to a&#xD;
             monoclonal antibody or fusion protein.&#xD;
&#xD;
         10. Previously been exposed to an immunosuppressive agent or biological agent (any other&#xD;
             than a monoclonal antibody or fusion protein) within 120 days prior to Randomisation.&#xD;
&#xD;
         11. Received live vaccine(s) within 30 days prior to Randomisation or who will require&#xD;
             live vaccine(s) during the study period.&#xD;
&#xD;
         12. A history of and/or current cardiac disease defined as one of the following:&#xD;
&#xD;
               1. Personal or family history of prolonged QT interval syndrome or Torsade de&#xD;
                  Pointes.&#xD;
&#xD;
               2. QT interval corrected by Fridericia's formulas &gt; 450 msec or PR interval outside&#xD;
                  the range 120 to 220 msec.&#xD;
&#xD;
               3. Signs and symptoms or any history suggestive for heart failure.&#xD;
&#xD;
               4. Any other cardiac abnormalities or conditions assessed as clinically significant.&#xD;
&#xD;
         13. Impaired liver, pancreas and biliary system as determined by one of the following:&#xD;
&#xD;
               1. Serum alanine transaminase and/or aspartate transaminase ≥ 1.5 times the upper&#xD;
                  limit of normal.&#xD;
&#xD;
               2. Gallbladder or bile duct disease classified as clinically significant.&#xD;
&#xD;
               3. Acute or chronic pancreatitis.&#xD;
&#xD;
               4. A positive hepatitis C virus antibody test or hepatitis B virus surface antigen&#xD;
                  test, or signs for active or chronic hepatitis B.&#xD;
&#xD;
               5. Hepatic disease classified as clinically significant.&#xD;
&#xD;
         14. A positive test result for human immunodeficiency virus, or have a history of&#xD;
             immunodeficiency.&#xD;
&#xD;
         15. A history of malignancy (including lymphoma and leukaemia) other than a successfully&#xD;
             treated non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma or&#xD;
             localised carcinoma.&#xD;
&#xD;
         16. Had surgery within 90 days prior to Randomisation, and/or who plan to have an&#xD;
             operation during the study period.&#xD;
&#xD;
         17. A history and/or current presence of an illness within 14 days prior to Randomisation&#xD;
             that is classified as clinically significant.&#xD;
&#xD;
         18. Have a history of and/or current Coronavirus Disease-19 (COVID-19) defined as one of&#xD;
             the following:&#xD;
&#xD;
               1. Positive test result for COVID-19 confirmed by severe acute respiratory syndrome&#xD;
                  coronavirus 2 (SARS-CoV-2) using real-time reverse transcriptase polymerase chain&#xD;
                  reaction (RT-PCR) at Day -1.&#xD;
&#xD;
               2. Signs and symptoms consistent with COVID-19 30 days prior to Randomisation.&#xD;
&#xD;
               3. Have had a positive test result for COVID-19 confirmed by SARS-CoV-2 detection&#xD;
                  using real-time RT-PCR.&#xD;
&#xD;
               4. Had severe course of COVID-19.&#xD;
&#xD;
         19. Smoked more than 10 cigarettes, 2 cigars or 2 pipes per day within 90 days prior to&#xD;
             Screening.&#xD;
&#xD;
         20. Regular consumption of alcoholic beverages that exceeds 14 units.&#xD;
&#xD;
         21. A positive urinary drug screening result.&#xD;
&#xD;
         22. Any prescription medicine or over-the-counter medicines (except paracetamol) that&#xD;
             might have an effect on the objectives of the study in the opinion of the&#xD;
             Investigator, within 30 days prior to Randomisation.&#xD;
&#xD;
         23. Donated &gt; 100 mL blood or plasma within 28 days prior to Randomisation.&#xD;
&#xD;
         24. Participated in another study with an investigational drug within 60 days prior to&#xD;
             Randomisation or are currently participating in or intending to participate in another&#xD;
             clinical study of an investigational drug before completion of all scheduled&#xD;
             evaluations in this clinical study.&#xD;
&#xD;
         25. Subjects who, in the opinion of the Investigator, are not likely to complete the study&#xD;
             for whatever reason.&#xD;
&#xD;
         26. Subject who is the Investigator or any sub-Investigator, research assistant,&#xD;
             pharmacist, study coordinator, other staff or relative thereof directly involved in&#xD;
             the conduct of the clinical study.&#xD;
&#xD;
         27. Vulnerable subjects.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Köernicke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International GmbH, Early Phase Clinical Unit Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH, Early Phase Clinical Unit Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

